Inactivation of FBXW7/hCDC4-β expression by promoter hypermethylation is associated with favorable prognosis in primary breast cancer

Breast Cancer Research

Volumn 12, Issue 6, 2010, Pages

  Akhoondi, Shahab ^a   Lindström, Linda ^a   Widschwendter, Martin ^c   Corcoran, Martin ^a   Bergh, Jonas ^a,b   Spruck, Charles ^d   Grandér, Dan ^a   Sangfelt, Olle ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b CHRISTIE HOSPITAL   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d BURNHAM INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; F BOX PROTEIN; MESSENGER RNA; PROTEIN P53; CELL CYCLE PROTEIN; FBXW7 PROTEIN, HUMAN; TUMOR MARKER; UBIQUITIN PROTEIN LIGASE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA METHYLATION; EPIGENETICS; FEMALE; FISHER EXACT TEST; GENE INACTIVATION; GENE MUTATION; HAZARD RATIO; HUMAN; HUMAN CELL; HUMAN TISSUE; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIMARY TUMOR; PROGNOSIS; PROMOTER REGION; PROPORTIONAL HAZARDS MODEL; PROTEIN EXPRESSION; PROTEIN METHYLATION; TUMOR SUPPRESSOR GENE; BREAST TUMOR; CPG ISLAND; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETICS; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; POLYMERASE CHAIN REACTION; SURVIVAL; TUMOR CELL LINE;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CPG ISLANDS; DNA METHYLATION; F-BOX PROTEINS; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; MULTIVARIATE ANALYSIS; POLYMERASE CHAIN REACTION; PROGNOSIS; PROMOTER REGIONS, GENETIC; RNA, MESSENGER; SURVIVAL; TUMOR MARKERS, BIOLOGICAL; UBIQUITIN-PROTEIN LIGASES;

EID: 78649494384     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2788     Document Type: Article

References (53)

1. Tan Y, Sangfelt O, Spruck C. The Fbxw7/hCdc4 tumor suppressor in human cancer. Cancer Lett 2008, 271:1-12. 10.1016/j.canlet.2008.04.036, 18541364.
2. Welcker M, Clurman BE. FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. Nat Rev Cancer 2008, 8:83-93. 10.1038/nrc2290, 18094723.
3. Orlicky S, Tang X, Willems A, Tyers M, Sicheri F. Structural basis for phosphodependent substrate selection and orientation by the SCFCdc4 ubiquitin ligase. Cell 2003, 112:243-256. 10.1016/S0092-8674(03)00034-5, 12553912.
4. Akhoondi S, Sun D, von der Lehr N, Apostolidou S, Klotz K, Maljukova A, Cepeda D, Fiegl H, Dafou D, Marth C, Mueller-Holzner E, Corcoran M, Dagnell M, Nejad SZ, Nayer BN, Zali MR, Hansson J, Egyhazi S, Petersson F, Sangfelt P, Nordgren H, Grander D, Reed SI, Widschwendter M, Sangfelt O, Spruck C. FBXW7/hCDC4 is a general tumor suppressor in human cancer. Cancer Res 2007, 67:9006-9012. 10.1158/0008-5472.CAN-07-1320, 17909001.
5. Hao B, Oehlmann S, Sowa ME, Harper JW, Pavletich NP. Structure of a Fbw7-Skp1-cyclin E complex: multisite-phosphorylated substrate recognition by SCF ubiquitin ligases. Mol Cell 2007, 26:131-143. 10.1016/j.molcel.2007.02.022, 17434132.
6. Knuutila S, Aalto Y, Autio K, Björkqvist AM, El-Rifai W, Hemmer S, Huhta T, Kettunen E, Kiuru-Kuhlefelt S, Larramendy ML, Lushnikova T, Monni O, Pere H, Tapper J, Tarkkanen M, Varis A, Wasenius VM, Wolf M, Zhu Y. DNA copy number losses in human neoplasms. Am J Pathol 1999, 155:683-694. 1866903, 10487825.
7. Rajagopalan H, Jallepalli PV, Rago C, Velculescu VE, Kinzler KW, Vogelstein B, Lengauer C. Inactivation of hCDC4 can cause chromosomal instability. Nature 2004, 428:77-81. 10.1038/nature02313, 14999283.
8. Matsuoka S, Oike Y, Onoyama I, Iwama A, Arai F, Takubo K, Mashimo Y, Oguro H, Nitta E, Ito K, Miyamoto K, Yoshiwara H, Hosokawa K, Nakamura Y, Gomei Y, Iwasaki H, Hayashi Y, Matsuzaki Y, Nakayama K, Ikeda Y, Hata A, Chiba S, Nakayama KI, Suda T. Fbxw7 acts as a critical fail-safe against premature loss of hematopoietic stem cells and development of T-ALL. Genes Dev 2008, 22:986-991. 10.1101/gad.1621808, 2335330, 18367647.
9. Mao JH, Perez-Losada J, Wu D, Delrosario R, Tsunematsu R, Nakayama KI, Brown K, Bryson S, Balmain A. Fbxw7/Cdc4 is a p53-dependent, haploinsufficient tumour suppressor gene. Nature 2004, 432:775-779. 10.1038/nature03155, 15592418.
10. Kimura T, Gotoh M, Nakamura Y, Arakawa H. hCDC4b, a regulator of cyclin E, as a direct transcriptional target of p53. Cancer Sci 2003, 94:431-436. 10.1111/j.1349-7006.2003.tb01460.x, 12824889.
11. Spruck CH, Strohmaier H, Sangfelt O, Müller HM, Hubalek M, Müller-Holzner E, Marth C, Widschwendter M, Reed SI. hCDC4 gene mutations in endometrial cancer. Cancer Res 2002, 62:4535-4539.
12. van Drogen F, Sangfelt O, Malyukova A, Matskova L, Yeh E, Means AR, Reed SI. Ubiquitylation of cyclin E requires the sequential function of SCF complexes containing distinct hCdc4 isoforms. Mol Cell 2006, 23:37-48. 10.1016/j.molcel.2006.05.020, 16818231.
13. Popov N, Herold S, Llamazares M, Schülein C, Eilers M. Fbw7 and Usp28 regulate myc protein stability in response to DNA damage. Cell Cycle 2007, 6:2327-2331. 10.4161/cc.6.19.4804, 17873522.
14. Moberg KH, Bell DW, Wahrer DC, Haber DA, Hariharan IK. Archipelago regulates Cyclin E levels in Drosophila and is mutated in human cancer cell lines. Nature 2001, 413:311-316. 10.1038/35095068, 11565033.
15. Malyukova A, Dohda T, von der Lehr N, Akhoondi S, Corcoran M, Heyman M, Spruck C, Grandér D, Lendahl U, Sangfelt O. The tumor suppressor gene hCDC4 is frequently mutated in human T-cell acute lymphoblastic leukemia with functional consequences for Notch signaling. Cancer Res 2007, 67:5611-5616. 10.1158/0008-5472.CAN-06-4381, 17575125.
16. Park MJ, Taki T, Oda M, Watanabe T, Yumura-Yagi K, Kobayashi R, Suzuki N, Hara J, Horibe K, Hayashi Y. FBXW7 and NOTCH1 mutations in childhood T cell acute lymphoblastic leukaemia and T cell non-Hodgkin lymphoma. Br J Haematol 2009, 145:198-206. 10.1111/j.1365-2141.2009.07607.x, 19245433.
17. Kwak EL, Moberg KH, Wahrer DC, Quinn JE, Gilmore PM, Graham CA, Hariharan IK, Harkin DP, Haber DA, Bell DW. Infrequent mutations of Archipelago (hAGO, hCDC4, Fbw7) in primary ovarian cancer. Gynecol Oncol 2005, 98:124-128. 10.1016/j.ygyno.2005.04.007, 15913747.
18. Bredel M, Bredel C, Juric D, Harsh GR, Vogel H, Recht LD, Sikic BI. Functional network analysis reveals extended gliomagenesis pathway maps and three novel MYC-interacting genes in human gliomas. Cancer Res 2005, 65:8679-8689. 10.1158/0008-5472.CAN-05-1204, 16204036.
19. Yokobori T, Mimori K, Iwatsuki M, Ishii H, Onoyama I, Fukagawa T, Kuwano H, Nakayama KI, Mori M. p53-Altered FBXW7 expression determines poor prognosis in gastric cancer cases. Cancer Res 2009, 69:3788-3794. 10.1158/0008-5472.CAN-08-2846, 19366810.
20. Iwatsuki M, Mimori K, Ishii H, Yokobori T, Takatsuno Y, Sato T, Toh H, Onoyama I, Nakayama KI, Baba H, Mori M. Loss of FBXW7, a cell cycle regulating gene, in colorectal cancer: clinical significance. Int J Cancer 2010, 126:1828-1837.
21. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002, 3:415-428. 10.1038/nrg962, 12042769.
22. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003, 349:2042-2054. 10.1056/NEJMra023075, 14627790.
23. Maier S, Lesche R, Nimmrich I, Eckhardt F, Dahlstroem C, Plum A. DNA methylation markers- an opportunity to further individualize therapy in breast cancer?. Personalized Medicine 2005, 2:339-347.
24. Fiegl H, Jones A, Hauser-Kronberger C, Hutarew G, Reitsamer R, Jones RL, Dowsett M, Mueller-Holzner E, Windbichler G, Daxenbichler G, Goebel G, Ensinger C, Jacobs I, Widschwendter M. Methylated NEUROD1 promoter is a marker for chemosensitivity in breast cancer. Clin Cancer Res 2008, 14:3494-3502. 10.1158/1078-0432.CCR-07-4557, 18519782.
25. Verma M, Seminara D, Arena FJ, John C, Iwamoto K, Hartmuller V. Genetic and epigenetic biomarkers in cancer: improving diagnosis, risk assessment, and disease stratification. Mol Diagn Ther 2006, 10:1-15.
26. Spruck C, Sun D, Fiegl H, Marth C, Mueller-Holzner E, Goebel G, Widschwendter M, Reed SI. Detection of low molecular weight derivatives of cyclin E1 is a function of cyclin E1 protein levels in breast cancer. Cancer Res 2006, 66:7355-7360. 10.1158/0008-5472.CAN-05-3240, 16849587.
27. Bergh J, Norberg T, Sjögren S, Lindgren A, Holmberg L. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat Med 1995, 1:1029-1034. 10.1038/nm1095-1029, 7489358.
28. Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A, Pawitan Y, Hall P, Klaar S, Liu ET, Bergh J. An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci 2005, 102:13550-13555. 10.1073/pnas.0506230102, 1197273, 16141321.
29. Sangfelt O, Cepeda D, Malyukova A, van Drogen F, Reed SI. Both SCF(Cdc4alpha) and SCF(Cdc4gamma) are required for cyclin E turnover in cell lines that do not overexpress cyclin E. Cell Cycle 2008, 7:1075-1082.
30. Zilberman D, Henikoff S. Genome-wide analysis of DNA methylation patterns. Development 2007, 134:3959-3965. 10.1242/dev.001131, 17928417.
31. Agrelo R, Cheng WH, Setien F, Ropero S, Espada J, Fraga MF, Herranz M, Paz MF, Sanchez-Cespedes M, Artiga MJ, Guerrero D, Castells A, von Kobbe C, Bohr VA, Esteller M. Epigenetic inactivation of the premature aging Werner syndrome gene in human cancer. PNAS 2006, 103:8822-8827. 10.1073/pnas.0600645103, 1466544, 16723399.
32. Image J software. , http://rsb.info.nih.gov/ij
33. DiNardo DN, Butcher DT, Robinson DP, Archer TK, Rodenhiser DI. Functional analysis of CpG methylation in the BRCA1 promoter region. Oncogene 2001, 20:5331-5340. 10.1038/sj.onc.1204697, 11536045.
34. Widschwendter M, Siegmund KD, Müller HM, Fiegl H, Marth C, Müller-Holzner E, Jones PA, Laird PW. Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen. Cancer Res 2004, 64:3807-3813. 10.1158/0008-5472.CAN-03-3852, 15172987.
35. Strohmaier H, Spruck CH, Kaiser P, Won KA, Sangfelt O, Reed SI. Human F-box protein hCdc4 targets cyclin E for proteolysis and is mutated in a breast cancer cell line. Nature 2001, 413:316-322. 10.1038/35095076, 11565034.
36. Li J, Pauley AM, Myers RL, Shuang R, Brashler JR, Yan R, Buhl AE, Ruble C, Gurney ME. SEL-10 interacts with presenilin 1, facilitates its ubiquitination, and alters A-beta peptide production. J Neurochem 2002, 82:1540-1548. 10.1046/j.1471-4159.2002.01105.x, 12354302.
37. Yamasaki L, Pagano M. Cell cycle, proteolysis and cancer. Curr Opin Cell Biol 2004, 16:623-628. 10.1016/j.ceb.2004.08.005, 15530772.
38. Nakayama KI, Nakayama K. Ubiquitin ligases: cell-cycle control and cancer. Nat Rev Cancer 2006, 6:369-381. 10.1038/nrc1881, 16633365.
39. Sterian A, Kan T, Berki AT. Mutational and LOH analyses of the chromosome 4q region in esophageal adenocarcinoma. Oncology 2006, 70:168-172. 10.1159/000094444, 16837775.
40. Hicks J, Krasnitz A, Lakshmi B, Navin NE, Riggs M, Leibu E, Esposito D, Alexander J, Troge J, Grubor V, Yoon S, Wigler M, Ye K, Børresen-Dale AL, Naume B, Schlicting E, Norton L, Hägerström T, Skoog L, Auer G, Månér S, Lundin P, Zetterberg A. Novel patterns of genome rearrangement and their association with survival in breast cancer. Genome Res 2006, 16:1465-1479. 10.1101/gr.5460106, 1665631, 17142309.
41. Tovey S, Dunne B, Witton CJ, Forsyth A, Cooke TG, Bartlett JM. Can molecular markers predict when to implement treatment with aromatase inhibitors in invasive breast cancer?. Clin Cancer Res 2005, 11:4835-4842. 10.1158/1078-0432.CCR-05-0196, 16000581.
42. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002, 20:719-726. 10.1200/JCO.20.3.719, 11821453.
43. Sharma G, Mirza S, Yang YH, Parshad R, Hazrah P, Datta Gupta S, Ralhan R. Prognostic relevance of promoter hypermethylation of multiple genes in breast cancer patients. Cell Oncol 2009, 31:487-500.
44. Chiang JW, Karlan BY, Cass L, Baldwin RL. BRCA1 promoter methylation predicts adverse ovarian cancer prognosis. Gynecol Oncol 2006, 101:403-410. 10.1016/j.ygyno.2005.10.034, 16360812.
45. Braggio E, Maiolino A, Gouveia ME, Magalhães R, Souto Filho JT, Garnica M, Nucci M, Renault IZ. Methylation status of nine tumor suppressor genes in multiple myeloma. Int J Hematol 2010, 91:87-96. 10.1007/s12185-009-0459-2, 20037750.
46. Morris MR, Ricketts C, Gentle D, Abdulrahman M, Clarke N, Brown M, Kishida T, Yao M, Latif F, Maher ER. Identification of candidate tumour suppressor genes frequently methylated in renal cell carcinoma. Oncogene 2010, 29:2104-2117. 10.1038/onc.2009.493, 20154727.
47. Asnafi V, Buzyn A, Le Noir S, Baleydier F, Simon A, Beldjord K, Reman O, Witz F, Fagot T, Tavernier E, Turlure P, Leguay T, Huguet F, Vernant JP, Daniel F, Béné MC, Ifrah N, Thomas X, Dombret H, Macintyre E. NOTCH1/FBXW7 mutation identifies a large subgroup with favorable outcome in adult T-cell acute lymphoblastic leukemia (T-ALL): a Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) study. Blood 2009, 113:3918-3924. 10.1182/blood-2008-10-184069, 19109228.
48. Finkin S, Aylon Y, Anzi S, Oren M, Shaulian E. Fbw7 regulates the activity of endoreduplication mediators and the p53 pathway to prevent drug-induced polyploidy. Oncogene 2008, 27:4411-4421. 10.1038/onc.2008.77, 18391985.
49. Gonzalez-Angulo AM, Hennessy BT, Mills GB. Future of Personalized Medicine in Oncology: A Systems Biology Approach. J Clin Oncol 2010, 28:2777-2783. 10.1200/JCO.2009.27.0777, 20406928.
50. Jiang H, Reinhardt HC, Bartkova J, Tommiska J, Blomqvist C, Nevanlinna H, Bartek J, Yaffe MB, Hemann MT. The combined status of ATM and p53 link tumor development with therapeutic response. Genes Dev 2009, 23:1895-1909. 10.1101/gad.1815309, 2725944, 19608766.
51. Takao N, Kato H, Mori R, Morrison C, Sonada E, Sun X, Shimizu H, Yoshioka K, Takeda S, Yamamoto K. Disruption of ATM in p53-null cells causes multiple functional abnormalities in cellular response to ionizing radiation. Oncogene 1999, 18:7002-7009. 10.1038/sj.onc.1203172, 10597300.
52. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ, Helleday T. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005, 434:913-917. 10.1038/nature03443, 15829966.
53. Mao JH, Kim IJ, Wu D, Climent J, Kang HC, DelRosario R, Balmain A. FBXW7 targets mTOR for degradation and cooperates with PTEN in tumor suppression. Science 2008, 321:1499-1502. 10.1126/science.1162981, 2849753, 18787170.